F Dx Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History

F Dx Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 17, 2023	BUY	$86.68 - $100.3 $214,619 - $248,342	2,476 New	2,476 $214,000
Q1 2021 Apr 13, 2021	SELL	$74.73 - $90.69 $202,443 - $245,679	-2,709 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$72.61 - $90.2 $196,700 - $244,351	2,709 New	2,709 $238,000
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $712,087 - $1.3 Million	-9,908 Closed	0 $0
Q2 2020 Jul 22, 2020	BUY	$79.55 - $124.22 $188,453 - $294,277	2,369 Added 31.42%	9,908 $1.22 Million
Q1 2020 May 22, 2020	BUY	$71.37 - $96.85 $315,669 - $428,367	4,423 Added 141.94%	7,539 $637,000
Q4 2018 Feb 07, 2019	BUY	$80.14 - $106.07 $249,716 - $330,514	3,116 New	3,116 $265,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.